Arctic Bioscience — Regulatory Filings 2024

Jan 17, 2024

Arctic Bioscience - Recruitment completed in the phase IIb HeROPA clinical trial

Arctic Bioscience - Recruitment completed in the phase IIb HeROPA clinical trial

With reference to the stock exchange announcement from December 1[st] 2023 which

reported more than 75% patients recruited to the phase IIb clinical trial

HeROPA, Arctic Bioscience is pleased to report that we have now fully recruited

this phase IIb clinical trial in mild-to-moderate psoriasis with the planned 519

patients.

The HeROPA trial is randomized, double blind and placebo controlled,

investigating the efficacy and safety of the novel, oral drug candidate HRO350

for the treatment of mild-to-moderate psoriasis. The HeROPA trial is ongoing in

5 countries in Europe; UK, Germany, Poland, Finland and Norway.

The HeROPA trial has had competitive recruitment at over 60 sites in the 5

countries to recruit the 519 patients. Fully recruiting this very large study is

a result of impressive efforts from over 60 sites across five countries. The

final recruited patients will be dosed in the next few weeks, and first data

-readout will be when all patients have been treated for 6 months, mid 2024.

We are grateful for the participation of dermatology clinics and patients with

mild-to-moderate psoriasis throughout Europe and the UK in the HeROPA study.

"We are very pleased to announce that our HeROPA clinical trial is now fully

recruited. This is a major milestone for Arctic Bioscience and a result of great

team effort by the employees in Arctic Bioscience, our CRO Smerud Medical

Research International and the 60+ clinics participating in the trial. With

this, we have taken another huge step forward in our medical program within mild

-to-moderate psoriasis.  After all patients have been dosed for 6 months, the

primary endpoint will be read out." says CEO Christer L. Valderhaug.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

Email: christer@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.